|Day Low/High||2.77 / 2.94|
|52 Wk Low/High||2.46 / 6.18|
Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million
R&D Facility an Important Milestone for ChromaDex to Continue Global Leadership in the Identification and Development of NAD+ Metabolites
Company's Scientific Advisory Board Will Be Comprised of a Diverse Range of Experts with an Emphasis on Nicotinamide Riboside
Company Will Host Investor Conference Call on Thursday, November 10, 2016
Researchers' findings disprove the idea that there's a shortcut to NAD production
This vitamin, called NR, is exciting researchers as they discover more about its power to give us a more youthful metabolism
AnthOrigin™ naturally extracted anthocyanins are ideal for natural, clean label supplement innovation
Booth to feature a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise
Booth to feature, a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise
NR, a vitamin B3, affords food and beverage manufacturers a new opportunity to innovate
-Company Reports Record Revenue of $8.8 Million and Operating Income of $371,000-
-Company Will Host Investor Conference Call on Thursday, August 11, 2016-
Study results will help to define the effective dose range of nicotinamide riboside (NR) in humans when taken daily, over eight weeks.
Levi & Korsinsky announces it has commenced an investigation of ChromaDex Corporation ("ChromaDex" or the "Company") (NASDAQ:CDXC) concerning possible violations of federal securities laws.